68 related articles for article (PubMed ID: 9658183)
1. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
[TBL] [Abstract][Full Text] [Related]
2. Interplay of isoprenoid and peptide substrate specificity in protein farnesyltransferase.
Reigard SA; Zahn TJ; Haworth KB; Hicks KA; Fierke CA; Gibbs RA
Biochemistry; 2005 Aug; 44(33):11214-23. PubMed ID: 16101305
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation.
Bratt JM; Chang KY; Rabowsky M; Franzi LM; Ott SP; Filosto S; Goldkorn T; Arif M; Last JA; Kenyon NJ; Zeki AA
J Immunol; 2018 Jun; 200(11):3840-3856. PubMed ID: 29703864
[TBL] [Abstract][Full Text] [Related]
4. Analogs of farnesyl diphosphate alter CaaX substrate specificity and reactions rates of protein farnesyltransferase.
Jennings BC; Danowitz AM; Wang YC; Gibbs RA; Distefano MD; Fierke CA
Bioorg Med Chem Lett; 2016 Feb; 26(4):1333-6. PubMed ID: 26803203
[TBL] [Abstract][Full Text] [Related]
5. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
O'Meara SJ; Kinsella BT
Biochem J; 2005 Feb; 386(Pt 1):177-89. PubMed ID: 15469414
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.
Hougland JL; Hicks KA; Hartman HL; Kelly RA; Watt TJ; Fierke CA
J Mol Biol; 2010 Jan; 395(1):176-90. PubMed ID: 19878682
[TBL] [Abstract][Full Text] [Related]
7. Upstream polybasic region in peptides enhances dual specificity for prenylation by both farnesyltransferase and geranylgeranyltransferase type I.
Hicks KA; Hartman HL; Fierke CA
Biochemistry; 2005 Nov; 44(46):15325-33. PubMed ID: 16285736
[TBL] [Abstract][Full Text] [Related]
8. Protein farnesyltransferase in plants: molecular characterization and involvement in cell cycle control.
Qian D; Zhou D; Ju R; Cramer CL; Yang Z
Plant Cell; 1996 Dec; 8(12):2381-94. PubMed ID: 8989889
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.
Reiners JJ; Mathieu PA; Gargano M; George I; Shen Y; Callaghan JF; Borch RF; Mattingly RR
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201517
[TBL] [Abstract][Full Text] [Related]
10. Farnesyl pyrophosphate is a new danger signal inducing acute cell death.
Chen J; Zhang X; Li L; Ma X; Yang C; Liu Z; Li C; Fernandez-Cabezudo MJ; Al-Ramadi BK; Wu C; Huang W; Zhang Y; Zhang Y; Liu W
PLoS Biol; 2021 Apr; 19(4):e3001134. PubMed ID: 33901180
[TBL] [Abstract][Full Text] [Related]
11. New tricks for human farnesyltransferase inhibitor: cancer and beyond.
Wang J; Yao X; Huang J
Medchemcomm; 2017 May; 8(5):841-854. PubMed ID: 30108801
[TBL] [Abstract][Full Text] [Related]
12. Library Screening, In Vivo Confirmation, and Structural and Bioinformatic Analysis of Pentapeptide Sequences as Substrates for Protein Farnesyltransferase.
Schey GL; Hildebrandt ER; Wang Y; Diwan S; Passetti HA; Potts GW; Sprague-Getsy AM; Leoni ER; Kuebler TS; Sham YY; Hougland JL; Beese LS; Schmidt WK; Distefano MD
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791363
[TBL] [Abstract][Full Text] [Related]
13. Structure-Guided Discovery of Potent Antifungals that Prevent Ras Signaling by Inhibiting Protein Farnesyltransferase.
Wang Y; Xu F; Nichols CB; Shi Y; Hellinga HW; Alspaugh JA; Distefano MD; Beese LS
J Med Chem; 2022 Oct; 65(20):13753-13770. PubMed ID: 36218371
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of protein farnesyltransferase substrate specificity using synthetic peptide libraries.
Krzysiak AJ; Scott SA; Hicks KA; Fierke CA; Gibbs RA
Bioorg Med Chem Lett; 2007 Oct; 17(20):5548-51. PubMed ID: 17804232
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.
Haney SL; Varney ML; Chhonker Y; Talmon G; Smith LM; Murry DJ; Holstein SA
Pharmacol Res; 2021 May; 167():105528. PubMed ID: 33667685
[TBL] [Abstract][Full Text] [Related]
16. Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.
Michael JV; Goldfinger LE
Semin Cancer Biol; 2019 Feb; 54():121-130. PubMed ID: 29203271
[TBL] [Abstract][Full Text] [Related]
17. The extracellular matrix protein EMILIN1 silences the RAS-ERK pathway via α4β1 integrin and decreases tumor cell growth.
Modica TME; Maiorani O; Sartori G; Pivetta E; Doliana R; Capuano A; Colombatti A; Spessotto P
Oncotarget; 2017 Apr; 8(16):27034-27046. PubMed ID: 28177903
[TBL] [Abstract][Full Text] [Related]
18. Transport to Rhebpress activity.
Garrido A; Brandt M; Djouder N
Small GTPases; 2016; 7(1):12-5. PubMed ID: 26735067
[TBL] [Abstract][Full Text] [Related]
19. How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.
Brock EJ; Ji K; Reiners JJ; Mattingly RR
Mini Rev Med Chem; 2016; 16(5):358-69. PubMed ID: 26423696
[TBL] [Abstract][Full Text] [Related]
20. Working together: Farnesyl transferase inhibitors and statins block protein prenylation.
Wojtkowiak JW; Gibbs RA; Mattingly RR
Mol Cell Pharmacol; 2009 Jan; 1(1):1-6. PubMed ID: 20419048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
